Trevena (NASDAQ:TRVN – Get Free Report) and KALA BIO (NASDAQ:KALA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.
Risk & Volatility
Trevena has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.03, meaning that its stock price is 303% less volatile than the S&P 500.
Earnings and Valuation
This table compares Trevena and KALA BIO’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Trevena | $3.12 million | 1.07 | -$40.29 million | ($2.68) | -1.46 |
| KALA BIO | $3.89 million | 4.42 | -$42.20 million | ($15.15) | -0.40 |
Profitability
This table compares Trevena and KALA BIO’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Trevena | N/A | -1,018.15% | -105.93% |
| KALA BIO | N/A | -366.43% | -66.41% |
Analyst Ratings
This is a breakdown of recent recommendations for Trevena and KALA BIO, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Trevena | 0 | 0 | 1 | 0 | 3.00 |
| KALA BIO | 0 | 0 | 2 | 0 | 3.00 |
Trevena currently has a consensus target price of $125.00, suggesting a potential upside of 3,096.93%. KALA BIO has a consensus target price of $16.50, suggesting a potential upside of 170.05%. Given Trevena’s higher possible upside, equities analysts plainly believe Trevena is more favorable than KALA BIO.
Insider and Institutional Ownership
13.6% of Trevena shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 2.4% of Trevena shares are held by company insiders. Comparatively, 13.4% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
KALA BIO beats Trevena on 8 of the 12 factors compared between the two stocks.
About Trevena
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
About KALA BIO
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
